Research into Congenital bleeding disorder spans multiple therapeutic approaches and trial phases.

23 total trials for this combination

Showing top 10 of 23 trials

Trials

NCT ID	Title	Status	Phase
NCT01395810	Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773	COMPLETED	PHASE3
NCT02141074	Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B	COMPLETED	PHASE3
NCT01467427	Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.	COMPLETED	PHASE3
NCT00984126	Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015	COMPLETED	PHASE3
NCT01228669	Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B	COMPLETED	PHASE1
NCT00486278	Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds	COMPLETED	PHASE2
NCT01480180	Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A	COMPLETED	PHASE3
NCT03528551	A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A	COMPLETED	PHASE3
NCT01731600	A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A	COMPLETED	PHASE3
NCT01489111	Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.	COMPLETED	PHASE3

Related Pages

All Congenital bleeding disorder trials All trials in London, United Kingdom